Riccetti Laura, Sperduti Samantha, Lazzaretti Clara, Klett Danièle, De Pascali Francesco, Paradiso Elia, Limoncella Silvia, Potì Francesco, Tagliavini Simonetta, Trenti Tommaso, Galano Eugenio, Palmese Angelo, Satwekar Abhijeet, Daolio Jessica, Nicoli Alessia, Villani Maria Teresa, Aguzzoli Lorenzo, Reiter Eric, Simoni Manuela, Casarini Livio
Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
International PhD School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Front Endocrinol (Lausanne). 2019 Jul 24;10:503. doi: 10.3389/fendo.2019.00503. eCollection 2019.
Recombinant follicle-stimulating hormone (FSH) (follitropin alfa) and biosimilar preparations are available for clinical use. They have specific FSH activity and a unique glycosylation profile dependent on source cells. The aim of the study is to compare the originator (reference) follitropin alfa (Gonal-f®)- with biosimilar preparations (Bemfola® and Ovaleap®)-induced cellular responses . Gonadotropin N-glycosylation profiles were analyzed by ELISA lectin assay, revealing preparation specific-patterns of glycan species (Kruskal-Wallis test; < 0.05, = 6) and by glycotope mapping. Increasing concentrations of Gonal-f® or biosimilar (1 × 10-1 × 10 ng/ml) were used for treating human primary granulosa lutein cells (hGLC) and FSH receptor (FSHR)-transfected HEK293 cells . Intracellular cAMP production, Ca increase and β-arrestin 2 recruitment were evaluated by BRET, CREB, and ERK1/2 phosphorylation by Western blotting. 12-h gene expression, and 8- and 24-h progesterone and estradiol synthesis were measured by real-time PCR and immunoassay, respectively. We found preparation-specific glycosylation patterns by lectin assay (Kruskal-Wallis test; < 0.001; = 6), and similar cAMP production and β-arrestin 2 recruitment in FSHR-transfected HEK293 cells (cAMP EC range = 12 ± 0.9-24 ± 1.7 ng/ml; β-arrestin 2 EC range = 140 ± 14.1-313 ± 18.7 ng/ml; Kruskal-Wallis test; ≥ 0.05; = 4). Kinetics analysis revealed that intracellular Ca increased upon cell treatment by 4 μg/ml Gonal-f®, while equal concentrations of biosimilars failed to induced a response (Kruskal-Wallis test; < 0.05; = 3). All preparations induced both 8 and 24 h-progesterone and estradiol synthesis in hGLC, while no different ECs were demonstrated (Kruskal-Wallis test; > 0.05; = 5). Apart from preparation-specific intracellular Ca increases achieved at supra-physiological hormone doses, all compounds induced similar intracellular responses and steroidogenesis, reflecting similar bioactivity, and overall structural homogeneity.
重组促卵泡激素(FSH)(果纳芬α)及其生物类似药制剂已可用于临床。它们具有特定的FSH活性和取决于来源细胞的独特糖基化谱。本研究的目的是比较原研(参比)果纳芬α(Gonal-f®)与生物类似药制剂(贝依®和奥佛丽®)诱导的细胞反应。通过ELISA凝集素测定分析促性腺激素N-糖基化谱,揭示聚糖种类的制剂特异性模式(Kruskal-Wallis检验;P<0.05,n = 6),并通过糖位作图进行分析。使用递增浓度的Gonal-f®或生物类似药(1×10 - 1×10 ng/ml)处理人原代颗粒黄体细胞(hGLC)和转染了FSH受体(FSHR)的HEK293细胞。通过BRET评估细胞内cAMP产生、Ca增加和β-抑制蛋白2募集,通过蛋白质印迹法评估CREB和ERK1/2磷酸化。通过实时PCR和免疫测定分别测量12小时基因表达以及8小时和24小时孕酮和雌二醇合成。我们通过凝集素测定发现了制剂特异性糖基化模式(Kruskal-Wallis检验;P<0.001;n = 6),并且在转染了FSHR的HEK293细胞中cAMP产生和β-抑制蛋白2募集相似(cAMP EC范围 = 12±0.9 - 24±1.7 ng/ml;β-抑制蛋白2 EC范围 = 140±14.1 - 313±18.7 ng/ml;Kruskal-Wallis检验;P≥0.05;n = 4)。动力学分析表明,用4μg/ml Gonal-f®处理细胞后细胞内Ca增加,而同等浓度的生物类似药未能诱导反应(Kruskal-Wallis检验;P<0.05;n = 3)。所有制剂均在hGLC中诱导了8小时和24小时孕酮及雌二醇合成,且未显示出不同的EC(Kruskal-Wallis检验;P>0.05;n = 5)。除了在超生理激素剂量下实现的制剂特异性细胞内Ca增加外,所有化合物均诱导了相似的细胞内反应和类固醇生成,反映出相似的生物活性和整体结构同质性。